Can a simple blood test tell who needs more cancer treatment?
NCT ID NCT06287814
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that looks for cancer DNA (called a liquid biopsy) can find leftover cancer cells after surgery in people with stage III colorectal cancer. The goal is to see if this test can help doctors decide who needs additional treatment and who can safely avoid it. The study will follow 70 patients for three years to see how well the test predicts cancer return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liquid biopsy (ctDNA blood test)
- What this could lead to
- If successful, this could help doctors know which patients need more treatment after surgery and which do not, reducing unnecessary side effects.
- What could go wrong
- This is an early-stage observational study with only 70 participants. The tests may not be accurate enough to guide treatment decisions yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Montpellier
RECRUITINGMontpellier, Hérault, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?